Press Room

Webinar: Evaluating the Best Formulations for Amorphous Solid Dispersions by Spray Drying

Start
Tuesday, February 28, 2023 - 16:00
End
Tuesday, February 28, 2023 - 17:28
Location: online
Webinar session 1 Spray Drying_Feb28 - SEM image of a particle in a dark green background

This is the first session of a three-part webinar series on Amorphous Solid Dispersions by Spray Drying: From Early Formulation to Commercial Lifecycle Management.

 

Watch On-demand.

Gated content. Registration is required.

 

 

Learn more about this webinar series here.

 

Featured Hovione experts in this webinar
Webinar Series Spray Drying Speakers - Alexandre Ribeiro | Hovione
Webinar Series Spray Drying Speakers - Ines Ramos | Hovione
Webinar Series Spray Drying Speakers - Pedro Monteiro | Hovione
Alexandre Ribeiro, Ph.D.

Senior Analytical Scientist 

R&D, Analytical Development
Inês Ramos, Ph.D.

Scientist 

R&D Oral Drug Product - Formulation Group
Pedro Monteiro, M.Sc. 

Scientist 

R&D Oral Drug Product - Formulation Group​​​​

 

Alexandre Ribeiro, Inês Ramos, and Pedro Monteiro kick-off the series by focusing on the role of amorphous solid dispersions in modern oral drugs and how the right formulation for a drug candidate can be selected using Hovione’s proprietary screening methodology. This method is performed via an automated high-throughput system that was developed over many years of experience with formulation of ASDs. The speakers will provide an understanding of the methodology, the evaluation process, and the studies typically utilized, as well as key information needed to make a formal assessment of the best candidates.

 

Your Key Learning Objectives

  • Understand the increasing importance of amorphous solid dispersions in oral drug delivery of new chemical entities
  • Get an overview of Hovione’s methodology to screen the best formulations in amorphous solid dispersions for a given API candidate
  • Learn about the formulation criteria based on stability, performance, and manufacturability data

 

Who Should Attend 

This webinar is suitable for anyone working in formulation of oral drugs, procurement, and outsourcing teams or as a project manager, who is interested in understanding the whole assessment process and their role in it.

 

 

 

Watch On-demand.

Gated content. Registration is required.

 

 

Do you have a challenging project needing differentiating technologies and an innovative approach?

Get in touch today

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026